Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
IODOTOPE is an oral capsule containing a radioactive iodine isotope, approved in 1957 as a diagnostic and therapeutic nuclear medicine agent. The mechanism involves selective uptake by the thyroid gland, enabling both imaging and treatment of thyroid disorders. This is a legacy small-molecule radiopharmaceutical with foundational importance in endocrinology.
Legacy product approaching loss of exclusivity with moderate competitive pressure; expect rightsizing of brand team and transition focus toward retained niche indications.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on IODOTOPE offers limited upside career trajectory but provides deep expertise in legacy radiopharmaceutical management, regulatory compliance, and niche therapeutic positioning. This role suits professionals seeking stability and specialized knowledge in an established product rather than launch or growth-stage opportunity.
Worked on IODOTOPE at Bracco? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.